Article Per Year (5 Year)
p-Index From 2021 - 2026
4.761
P-Index
This Author published in this journals
All Journal Farmasains : Jurnal Farmasi dan Ilmu Kesehatan Jurnal Kedokteran Brawijaya Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Media Farmasi : Jurnal Ilmu Farmasi (Journal Of Pharmaceutical Science) Jurnal Kesehatan Jurnal Farmasi Klinik Indonesia Pharmacon MPI (Media Pharmaceutica Indonesiana) Pharmascience JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Pharmasipha PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) JFIOnline Pharmaceutical Journal of Indonesia JFM (Jurnal Farmasi Malahayati) JURNAL FARMASIMED (JFM) Majalah Farmasetika Jurnal Ilmiah Farmasi Farmasyifa Budapest International Research in Exact Sciences (BirEx Journal) Hubungan Tingkat Pengetahuan Petugas Pengelola Obat dengan Tingkat Ketersediaan Obat Di Puskesmas Kota Malang Jurnal Farmasi dan Sains Indonesia (JFSI) Indonesian Journal of Pharmaceutical Education Jurnal Riset Farmasi Journal of Global Pharma Technology Journal of Tropical Pharmacy and Chemistry Jurnal Sains dan Kesehatan Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Folia Medica Indonesiana
Didik Hasmono
Department Of Clinical Pharmacy, Faculty Of Pharmacy, Universitas Airlangga
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemistry Civil Engineering, Building, Construction & Architecture Education Environmental Science Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Nursing Physics Public Health Transportation Other

Published : 74 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search
Journal : Jurnal Kesehatan

 1 
STUDY OF EFFECTIVENESS AND SIDE EFFECTS OF FAVIPIRAVIR THERAPY ON MILD AND MODERATE COVID-19 PATIENTS Didik Hasmono; Alfa Frista Arta; Ismawati; Ruddy Hartono; Mohammad Subhan
Jurnal Kesehatan Vol 15 No 2 (2022): JURNAL KESEHATAN
Publisher : Universitas Islam Negeri Alauddin Makassar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24252/kesehatan.v15i2.29380

Abstract

Introduction: Corona Virus Disease-2019 (COVID-19) is divided into five degrees that are asymptomatic, mild, moderate, severe and critical. Recently, Favipiravir known as off-label antivirals for COVID-19 that inhibits RNA-dependent RNA polymerase (RdRp) and is administered orally 2x1600 mg as loading dose and 2x600 mg as a maintenance dose. Methods: This observational retrospective study aims to determine effectiveness (PCR/Rapid Ag, temperature, respiratory rate, oxygen saturation, and chest X-ray) and side effects (digestive, uric acid, liver, blood, glucose, and lipids profile) of Favipiravir in mild and moderate COVID-19; which inclusion criteria were Favipiravir (5-10 days); a group of antibacterials: Azithromycin (therapy A), Levofloxacin (therapy B), and combination (therapy C); vitamins, minerals, symptomatic and comorbid therapy; and Fondaparinux used in moderate degree then described quantitatively. Results: This study obtained 47 HMR dominated by males (55%), aged 19-30 years (36%), cough symptoms (72,3%), and no comorbid status (70.2%). Favipiravir (6-7 days) is effective for mild and moderate degree in all effectiveness parameters with average length in mild degree was 6-12 days and moderate degree was 8-13 days. Possible interaction with Paracetamol was found. Most side effects were diarrhea and no significant side effects were found on liver profile (AST and ALT), glucose profile, and blood profile (leukocytes and erythrocytes). Conclusions: This result suggests that increasing collaboration of pharmacists with other healthcare in monitoring the use of Favipiravir related to interactions, uric acid, and lipid profiles, also effects in patients under 18 years, men, and elderly is important.
STUDI PENGGUNAAN LOPINAVIR/RITONAVIR PADA PASIEN COVID-19 DERAJAT RINGAN-SEDANG DENGAN KOMORBID HIPERTENSI DAN DIABETES MELLITUS Didik Hasmono; Agriawan Sudirman; Muhammad Nashrullah; Ruddy Hartono; Mohammad Subhan
Jurnal Kesehatan Vol 16 No 1 (2023): JURNAL KESEHATAN
Publisher : Universitas Islam Negeri Alauddin Makassar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24252/kesehatan.v16i1.28711

Abstract

Lopinavir/Ritonavir is proposed as one of the therapy for Covid-19 patients based on the ability to reduce viral load. Bhayangkara Hospital Surabaya is one of the hospitals with quite a lot of Covid-19 patients in Surabaya. The research aimed to determine the effectiveness, outcome, and evaluate side effects of Lopinavir/Ritonavir in mild to moderate Covid-19 patients with comorbid hypertension and diabetes mellitus at Bhayangkara Hospital Surabaya. This was an observational study that collected data retrospectively at Bhayangkara Hospital Surabaya. Patient data had to meet the requirements for inclusion criteria, which were patients treated with Lopinavir/Ritonavir for a Covid-19 mild to moderate with comorbid hypertension and diabetes mellitus. Data were obtained from 18 patient medical records and then processed descriptively. The results showed that 7 patients (39%) received therapy A with 11 days of treatment, 4 patients received therapy B (22%) with 12 days of treatment, 1 patient (11%) received therapy C with 18 days of treatment, and 6 patients (28%) on D therapy with 14 days of treatment. Patients experiencing effects of gastrointestinal disturbances such as nausea (22%), and diarrhea (11%). Lopinavir/Ritonavir in therapy A is the most effective when viewed from the length of treatment, which is 11 days. Therapy B, C, and D were considered effective as seen from the results of RT-PCR which showed negative results, namely 100%. Therapy D is the most effective chest X-ray repair, which is 50%. Side effects of Lopinavir/Ritonavir were gastrointestinal disturbances, namely nausea (22%), and diarrhea (11%), while hepatotoxicity was not found.
STUDI PENGGUNAAN DEKSAMETASON PADA PASIEN COVID-19 DERAJAT BERAT DENGAN KOMORBID DIABETES MELLITUS Hasmono, Didik; As-Shiddiq, Hasbi; Insyirah Idris, Anissah; Agriawan Sudirman; Hartono, Ruddy; Subhan, Mohammad
Jurnal Kesehatan Vol 16 No 2 (2023): : JURNAL KESEHATAN
Publisher : Universitas Islam Negeri Alauddin Makassar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24252/kesehatan.v16i2.28712

Abstract

Administration of Dexamethasone in patients with diabetes needs attention because corticosteroids can increase blood glucose concentrations. Therefore, this study aims to determine the effectiveness of using Dexamethasone in patients with severe COVID-19 and how to regulate blood glucose in patients with severe COVID-19 in patients with comorbid Diabetes Mellitus. Inclusion criteria for severe COVID-19 patients with comorbid Diabetes Mellitus who use Dexamethasone and therapy groups and receive insulin therapy with or without OAD in inpatient installations. The sample data obtained from the patient's medical records were 27 patients who met the inclusion and exclusion criteria consisting of 70% male and 30% female. Dexamethasone dose of 1 x 6 mg iv mostly uses combination therapy A, the duration of administration is 8 days, and has an average length of stay of 13 days. The shortest average length of hospitalization was 12 days for patients receiving dexamethasone with therapy C for 10 days, while therapy B for 5 days had an average hospitalization of 14 days. Administration of Dexamethasone dose of 1 x 6 mg iv is effective in severe COVID-19 patients with comorbid Diabetes Mellitus based on the length of hospitalization, respectively 13 days, 14 days, and 12 days with an improvement in the clinical condition of oxygen saturation by 91%, 100%, 100%; RT-PCR/Rapid Ag became negative 74%, 100%, 100%; improvement of chest x-ray results, namely 83%, 33%, 100%. The effect of glucocorticoid dexamethasone in comorbid Diabetes Mellitus patients is regulated by administering long-acting insulin, rapid-acting insulin, and oral anti-diabetic.
Co-Authors Adinugraha Amarullah Aghnia Fuadatul Inayah Agriawan Sudirman Agriawan Sudirman Agus Sunarko Agus Sunarko Alfa Frista Arta Alfin Giovani Amanda, Anita Tria Amarullah, Adinugraha Andilusia, Sindy Ardianty, Nonie Arina Dery Puspitasari Aryani, Dhita Aryani, Dhita Evi Astutik, Widi Atika Putri Kusumaningtyas Atmajani, Wanudya Awdisma, Wien Maryati Ayumuyas, Nur Palestin Ayumuyas, Nur Palestin Ayunda Nur Hidayatiningsih Badriyah, Rani Nur Bambang Sidharta Binti Muzayyanah Budi Suprapti Budiatin, Aniek Setiya Bura, Ursula Dua Klowe Chrysnanda Maryska Claudia Tiffany Dea Ayu Nabilah Dinda Monika Nusantara Ratri Dini Setiya Praja Dini Setiya Praja, Dini Setiya Donsu, Yosefien Christania Elisabeth Kasih Fadlilah, Umul Firandi, Adelia Ganesha T Trengginas Giovani, Alfin Hadiyanti, Nur Hanum, Putri Safitri Hariyati, Fera Hariyati, Fera Hartono, Ruddy Hasbi As-Shiddiq Hendra Yadi Heni Pujiastuti Hidajah Rachmawati Hidajah Rachmawati Hidayah Karuniawati Hidayah, Ana Nurlaili IGD Ugrasena Ilfi Hanna, Az Zahra Insyirah Idris, Anissah Irianto, Jimmy Setiawan Irsan Fahmi Almuhtarihan Irsan Fahmi Almuhtarihan Ismawati Isparnadi, Erwien Issaura, Issaura Jenggo Suwarko Joko Semedi Junaidi Khotib Khairil Armal Kuntaman Kuntaman Kusumaningrum , Yunita Dyah Kusumaningtyas, Atika Putri Lilik Yusetyani Lilik Yusetyani Ma'rifah, Nurul Machin, Abdulloh Mahardian Rahmadi Mareta Rindang Andarsari Maria Angelia Yoshida Meiliana, Made Laksmi Meo, Maria Lettisia Mia Melinda Mohammad Saiful Islam Mohammad Saiful Islam, Mohammad Saiful Mohammad Subhan Mohammad Subhan Mohammad Subhan Mohammad Subkhan Muhammad Nashrullah Muktamiroh Muktamiroh Muzayyanah, Binti Nadriatul Utami Nadriatul Utami Nailis Syifa Ni Made Eravikania Putri Darmawan Nun Zairina, Nun Nur Hadiyanti Nuraida Wisudani Nurfausiah, Nurfausiah Nurmainah Nurmainah Nurul Ma'rifah Paulus Sugianto Pharmasinta Putri Hapsari Pramadani, Yana Puri Safitri Hanum Puspitasari, Diny Putri Nurhidayah, Eka Ramdani, Dewi Retna Dwi Puspitarini Rino Wahyudi, Rino Risa Septinia Rizki Lisya Nugraha Roni Subagyo RR. Ella Evrita Hestiandari Ruddy Hartono Ruddy Hartono Ruddy Hartono Ruddy Hartono Ruhaya Fitrina, Ruhaya Samirah Samirah Sandra J. Parambang Sandra, Pipit Semedi, Joko Sendi Lia Yunita Setiawan, Landia Siti Surdijati Siti Surdijati, Siti Sofiati Diah Baisuni Subagyo, Roni Suharjono Suharjono, Suharjono Sumarno Sumarno Syifa', Nailis Syifa, Nailis' Tanasy, Marledy Taufiqur Rahman, Taufiqur Thayyib, Muqoddar Tista Ayu Fortuna Trengginas, Ganesha T Ugrasena, IGD Ulfa Syafli Nosa Usman Hadi Utami, Nadriatul Wardhani, Firdha Aprillia Wardhani, Hety Setya Widi Astutik Widi Astutik Wien Maryati Awdisma Wiranata, I Made Wisudani, Nuraida Worotikan, Natania Imanuella Yosefien Christania Donsu Yudi Agung Wibisono Yudistira Nurrizky Grahitaning Putra Rohmaana Yulistiani Yulistiani Yulistiani Yulistiani, Yulistiani Yulistiani, . Yuni, Santi Eka Yuni, Santi Eka